Prostate Cancer
The polyunsaturated fatty acid docosahexaenoic affects mitochondrial function in prostate cancer cells.
September 19, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testing.
September 19, 2024
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).
September 19, 2024
Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer.
September 19, 2024
Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project.
September 19, 2024
Survival of men with metastatic hormone-sensitive prostate cancer and adrenal-permissive HSD3B1 inheritance.
September 19, 2024
Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer.
September 19, 2024
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.
September 19, 2024
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.
September 18, 2024
Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging.
September 18, 2024
Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy: A Secondary Analysis of a Randomized Clinical Trial.
September 18, 2024
Evolving Paradigms in Prostate Cancer: The Integral Role of PSMA PET/CT in Primary Staging and Therapeutic Decision-Making.
September 18, 2024
Physician Perspectives on the Nonclinical Factors That Contribute to Decision-Making for Advanced Prostate Cancer Care: A Qualitative Study.
September 18, 2024
Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy.
September 18, 2024
A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.
September 18, 2024